Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 3 trials in your specialties ()
View trials across your selected specialties

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
View Full Trial
INTERVENTION

Drug: CC-90009

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Hosptial La Fe, Valencia, Spain

Brief Summary

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk myelodysplastic syndrome.

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

  • Status
    Not yet recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Leukemia, Myeloid, Acute
View Full Trial
INTERVENTION

Drug: CC-90009, Drug: Venetoclax, Drug: Azacitidine, Drug: Gilteritinib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of California, San Francisco, San Francisco, California, United States

Brief Summary

CC-90009-AML-002 is an exploratory Phase 1b open-label multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in subjects with acute myeloid leukemia (AML).

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

  • Status
    Not yet recruiting
  • Phase
    Phase 1
  • Condition
    Healthy Volunteer
View Full Trial
INTERVENTION

Drug: CC-90009, Radiation: [14C]

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: Male
  • Accepts Healthy Volunteers: Yes
Locations

Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

Brief Summary

CC-90009-CP-001 is a Phase 1, single-center, open-label, clinical pharmacology study to measure how much CC 90009 gets into the bloodstream, how much is eliminated in urine and stool, and how long it takes the body to get rid of it. In addition, the safety and tolerability of CC 90009 will be evaluated.